×
About 3,473 results

Top Medications Most Often Linked to Headache
https://www.medscape.com/viewarticle/976124

Jun 23rd, 2022 - DENVER, Colorado — Monoclonal antibodies, antivirals, immunomodulators, and pulmonary arterial vasodilators top the list of drugs that were most frequently implicated as causes of headaches in a federal side effect database that anyone can contribute to, according to a new study presented at the annual meeting of the American Headache Society. Brett Musialowicz "Surprising findings included the...

FDA Approves Risankizumab (Skyrizi) for Crohn’s Disease
https://www.medscape.com/viewarticle/975829

Jun 17th, 2022 - The US Food and Drug Administration (FDA) has approved risankizumab-rzaa (Skyrizi, AbbVie) for a third indication — treatment of moderately to severely active Crohn’s disease in adults — making it the first specific anti-interleukin 23 (IL-23) monoclonal antibody indicated for Crohn’s disease. The safety and efficacy of risankizumab in Crohn’s disease is supported by data from two induction cli...

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03789240

Jun 16th, 2022 - Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin s lymphoma (NHL) with a highly variable clinical course across patients Standard frontline therapy for FL includes a monoclonal anti-CD20 antibody with or without chemotherapy that can induce durable remissions but is generally not curable The 20% of patients who relapse within 2 years of frontline chemotherapy have an...

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

Jun 16th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse after frontline therapy are at high risk for treatment failure Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive B-cell lymp...

Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03321643

Jun 16th, 2022 - PRIMARY OBJECTIVES: I. Assess the safety and toxicity of atezolizumab in combination with immunogenic chemotherapy (gemcitabine plus oxaliplatin) with rituximab (R-GEMOX-ATEZO) in patients with relapsed or refractory (rel/ref) transformed diffuse large B-cell lymphoma (DLBCL), including determination of the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of R-GEMOX-ATEZO. ...

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04002947

Jun 16th, 2022 - Background: Gene-expression profiling (GEP) has identified two dominant molecular subtypes, activated B cell like (ABC) and germinal center B cell like (GCB), that arise by distinct mechanisms, have distinct prognoses, and respond differently to targeted therapy Recently, genetic subtypes of DLBCL have been described within molecular subtypes that have distinct genotypic, epigenetic, and clinic...

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02203526

Jun 16th, 2022 - Background: Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included high dose methotrexate and radiation treatment. Most PCNSLs appear to be of activated B-cell (ABC) origin Ibrutinib is an inhibitor of Bruton s tyrosine...

Venetoclax Combos Improve Progression-Free Survival in CLL
https://www.medscape.com/viewarticle/975652

Jun 15th, 2022 - Use of the targeted therapy combination of venetoclax plus obinutuzumab for fit patients with chronic lymphocytic leukemia (CLL) significantly improved progression-free survival (PFS) at 3 years compared with standard chemoimmunotherapy, new phase 3 data show. Adding the BTK inhibitor ibrutinib to the two-drug combination pushed the 3-year PFS even higher, but the risk of severe adverse events ...

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
https://clinicaltrials.gov/ct2/show/NCT04404283

Jun 14th, 2022 - Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, b...

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02048813

Jun 13th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the ability of ibrutinib-based induction therapy to prolong progression free survival (PFS) compared to standard fludarabine phosphate, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy for younger patients with chronic lymphocytic leukemia (CLL). SECONDARY OBJECTIVES: I. Evaluate overall survival (OS) of patients based on treatment arm. II. Monitor and ...

Novel Drug Tied to Slowed Disease Progression in Relapsing MS
https://www.medscape.com/viewarticle/975368

Jun 10th, 2022 - NATIONAL HARBOR, Maryland — Ublituximab (TG Therapeutics, Inc), an investigational anti-CD20 monoclonal antibody infused once every 6 months, is effective for treating relapsing forms of multiple sclerosis (RMS), new research suggests. Pooled analysis of the phase 3 ULTIMATE I and II trials, including more than 1000 total patients with RMS, showed significant improvements on several measures of...

A New First-line Regimen for Advanced Hodgkin Lymphoma?
https://www.medscape.com/viewarticle/975410

Jun 10th, 2022 - Patients with advanced classical Hodgkin lymphoma treated with first line brentuximab vedotin (Adcetris) plus chemotherapy showed substantial improvements in overall survival compared with those receiving standard chemotherapy, new research shows. Over a follow-up of 6 years, patients on brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) had a 41% lower risk of death vs ...

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
https://clinicaltrials.gov/ct2/show/NCT01938001

Jun 10th, 2022 - Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is an immunomodulatory drug (a drug that affects the immune system) which alters the body's immune system and it may also interfere with the development o...

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02953509

Jun 10th, 2022 - The primary objectives of this study are: To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and ...

Novel Drug Safe, Effective in Relapsing MS: 2-Year Data 
https://www.medscape.com/viewarticle/975313

Jun 9th, 2022 - NATIONAL HARBOR, Maryland — Evobrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor for relapsing multiple sclerosis (RMS), is relatively safe and effective over the long-term, new research suggests. Results from the longest follow-up of any BTK inhibitor drug for MS to-date show efficacy over 2½ years in slowing neurodegeneration in the disease. In addition, "extended experien...

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular ...
https://clinicaltrials.gov/ct2/show/NCT05409066

Jun 8th, 2022 - Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refr...

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04384484

Jun 8th, 2022 - The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

Izokibep Improves Multiple PsA Symptoms in Phase 2 Study
https://www.medscape.com/viewarticle/975169

Jun 7th, 2022 - A host of psoriatic arthritis symptoms can be improved by the investigational interleukin (IL)-17 blocker izokibep, according to the results of a phase 2 trial presented at the annual European Congress of Rheumatology. Around half of all participants in the trial who were treated with izokibep achieved a 50% or higher improvement in American College of Rheumatology response criteria (ACR50) at ...

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01661881

Jun 7th, 2022 - This was a PII single-arm design to determine whether the regimen looked promising for further study. Primary Objective • To evaluate the efficacy of an alternating regimen of Rituximab-Bendamustine and Rituximab-Cytarabine (RB/RC) using the CR/Cru rate. Secondary Objectives To assess safety. To estimate the rate of complete remission (CR), unconfirmed CR (CRu), partial remission (PR), stable d...

Inebilizumab Beneficial Across Genotypes in NMOSD
https://www.medscape.com/viewarticle/975143

Jun 6th, 2022 - NATIONAL HARBOR, Md. — Treating neuromyelitis optica spectrum disorder (NMOSD) with the recently approved monoclonal antibody inebilizumab (Uplizna, Horizon Therapeutics) is effective across patient genotypes — including a common genetic variation linked to reduced response to anti-CD20 therapies, new research shows. The phase 3 N-MOmentum Study previously showed safety and efficacy for inebili...